Genomma Lab Internacional, S.A.B. de C.V. v. Mprezas, Inc.

District Court, N.D. California·Decided December 20, 2023·No. 3:22-cv-01759·Unknown

Opinion

GENOMMA LAB INTERNACIONAL, Case No. 3:22-cv-01759-WHO S.A.B. DE C.V., Plaintiff, ORDER ON MOTION TO DISMISS AND STRIKE THIRD AMENDED v. COMPLAINT MPREZAS, INC., et al., Re: Dkt. No. 87 Defendants.

Plaintiff Genomma Lab Internacional, S.A.B. de C.V. (“Genomma”) filed this trademark infringement suit against defendants Mprezas, Inc.; iBrand Holdings, LLC; OPMX, LLC; Martha Nancy Hernandez; and Fernando Eduardo Bedoy Garces (collectively, “the defendants”). In its third amended complaint, Genomma newly asserts that the defendants fraudulently procured registration of their TWKOF and TUTOX trademarks. The defendants move to dismiss those new claims, move to dismiss all claims against Bedoy Garces, and move to strike several allegations in the operative complaint. For the following reasons, the motion is granted in part and denied in part. The factual background of this case is laid out in my Prior Order, [Dkt. No. 83], and this Order assumes familiarity with those facts, which are repleaded in the Third Amended Complaint (“TAC”), [Dkt. No. 86]. In a nutshell, Genomma asserts that the defendants’ TWKOF and TUTOX marks, labels, and products infringe on Genomma’s trademark and copyright for its TUKOL cough medicine products. See Prior Order Background. Additional relevant facts from the TAC are as follows. applied to the United States Patent and Trademark Office (“USPTO”) for a trademark because she used a W and an F in the registration but the label itself appears to use a U and an L. TAC ¶¶ 89, 91. Genomma also says that Hernandez falsely told the USPTO that she did not know of other confusingly similar marks used in commerce. Id. ¶¶ 90-92. According to Genomma, this was all because Hernandez intended to deceive the USPTO. Id. ¶ 30. Genomma alleges that the USPTO “accepts” but “does not verify” information in the registrations provided by the applications. Id. ¶¶ 90-91, 93. Genomma also appears to assert that before selling the TWKOF or TUTOX products, the defendants were required to register with the Food and Drug Administration (“FDA”) and receive a “National Drug Code.” Id. ¶¶ 47-48, 52-55. It states that the defendants did not do so for TUTOX at least as of February 27, 2023, yet Hernandez submitted a sworn declaration to the USPTO that the mark was used in commerce at least by that date. See id. ¶ 107-10. Genomma further alleges that the TUTOX packaging label provided to the USPTO in the application was not the real TUTOX label but rather an edited version of the TWKOF label designed to help the defendants register the mark. Id. Additionally, Genomma alleges that individual defendant Fernando Eduardo Bedoy Garces1 is the sole manager and employee of iBrand, a Wyoming LLC, and the sole owner and manager of OPMX, a Delaware LLC. Id. ¶¶ 10, 12, 15-16. It asserts that Bedoy Garces did not provide his location of residence during his deposition, but it believes he lives in Southern California due to conditions of his current probation. Id. ¶ 14. According to Genomma, Mprezas assigned its TWKOF trademark to iBrand in April 2022. Id. ¶ 39. Bedoy Garces signed the agreement and filed the assignment with the USPTO. Id. Genomma alleges that at that time, Bedoy Garces knew that the TWKOF mark was being misused to confuse and deceive customers. Id. ¶ 40. It asserts that OPMX, and therefore Bedoy Garces, are responsible for the TWKOF design. Id. ¶¶ 61-63. The TAC asserts six causes of action: (1) trademark infringement under 15 U.S.C. § 1114,2 id. ¶¶ 64-72; (2) unfair competition under 15 U.S.C. § 1125(a)(1)(A), id. ¶¶ 73-78; (3) trade dress infringement, id. ¶¶ 79-86; (4) fraudulent procurement of the TWKOF mark under 15 U.S.C. § 1064, id. ¶¶ 87-96; (5) copyright infringement under 17 U.S.C. §§ 101 et seq., id. ¶¶ 97-103; and (6) fraudulent procurement of the TUTOX mark under 15 U.S.C. § 1064, id. ¶¶ 105-13. The defendants filed a motion to dismiss the two fraudulent procurement claims and all claims against Bedoy Garces, as well as a motion to strike certain allegations in the TAC and two requests for judicial notice. (“Mot.”) [Dkt. No. 87]. Genomma opposed. (“Oppo.”) [Dkt. No. 89]. The defendants replied. (“Repl.”) [Dkt. No. 90]. I held a hearing at which counsel for both parties appeared. I. RULE 12(B)(6) Under Federal Rule of Civil Procedure (“FRCP”) 12(b)(6), a district court must dismiss a complaint if it fails to state a claim upon which relief can be granted. To survive a Rule 12(b)(6) motion to dismiss, the plaintiff must allege “enough facts to state a claim to relief that is plausible on its face.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007). A claim is facially plausible when the plaintiff pleads facts that “allow the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (citation omitted). There must be “more than a sheer possibility that a defendant has acted unlawfully.” Id. While courts do not require “heightened fact pleading of specifics,” a plaintiff must allege facts sufficient to “raise a right to relief above the speculative level.” Twombly, 550 U.S. at 555, 570. In deciding whether the plaintiff has stated a claim upon which relief can be granted, the Court accepts the plaintiff’s allegations as true and draws all reasonable inferences in favor of the plaintiff. See Usher v. City of Los Angeles, 828 F.2d 556, 561 (9th Cir. 1987). However, the court

Free access — add to your briefcase to read the full text and ask questions with AI

Genomma Lab Internacional, S.A.B. de C.V. v. Mprezas, Inc., (N.D. Cal. 2023).

Genomma Lab Internacional, S.A.B. de C.V. v. Mprezas, Inc. (Genomma Lab Internacional, S.A.B. de C.V. v. Mprezas, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
United States v. Corinthian Colleges
655 F.3d 984 (Ninth Circuit, 2011)
United States v. J. Alexis Caparros
800 F.2d 23 (Second Circuit, 1986)
Nazzaro Scarpa v. Larry E. Dubois, Etc.
38 F.3d 1 (First Circuit, 1994)
Kearns v. Ford Motor Co.
567 F.3d 1120 (Ninth Circuit, 2009)
In Re Gilead Sciences Securities Litigation
536 F.3d 1049 (Ninth Circuit, 2008)
Rosales v. Citibank, Federal Savings Bank
133 F. Supp. 2d 1177 (N.D. California, 2001)
Platte Anchor Bolt, Inc. v. IHI, INC.
352 F. Supp. 2d 1048 (N.D. California, 2004)
Aureflam Corp. v. Pho Hoa Phat I, Inc.
375 F. Supp. 2d 950 (N.D. California, 2005)
eCash Technologies, Inc. v. Guagliardo
210 F. Supp. 2d 1138 (C.D. California, 2001)
Hokto Kinoko Company v. Concord Farms, Inc.
738 F.3d 1085 (Ninth Circuit, 2013)
United States v. Ayala-Vazquez
751 F.3d 1 (First Circuit, 2014)
Shahin v. Geithner
84 F. Supp. 3d 1 (District of Columbia, 2015)
Lien Huynh v. Chase Manhattan Bank
465 F.3d 992 (Ninth Circuit, 2006)